SLC2A1 and cancer: Furthermore, the phenomenon of cancer chemoresistance, characterized by the aberrant expression of GLUT1, is also evident in DDP resistance of ovarian cancer and the acquired imatinib resistance of gastrointestinal stromal tumor cells (Loar et al. 2010; Shima et al. 2022).